What is ‘Scromiting’? ER Doctors Are Seeing It More

Cannabinoid hyperemesis syndrome (CHS), a condition characterized by intense abdominal pain and vomiting – often accompanied by screaming – is on the rise. The phenomenon has left medical professionals scrambling to understand its causes and consequences.

The connection between CHS and cannabis use is not new; studies have shown that individuals who regularly consume high-potency marijuana are at increased risk of developing this condition. However, the sheer number of cases reported in emergency departments nationwide suggests a more profound issue at play.

In 2025, the introduction of ICD 10 codes for CHS marked an important milestone in recognizing the syndrome as a legitimate medical concern. Yet, despite growing awareness among healthcare professionals, many patients remain unaware of the potential risks associated with cannabis use. The narrative surrounding marijuana’s benefits and risks has become increasingly politicized, leaving consumers to navigate a complex landscape of misinformation.

CHS is often mistaken for cyclic vomiting syndrome (CVS), a condition that affects both children and adults. Dr. Thangam Venkatesan, an expert on CVS at Ohio State University, notes that patients with CHS exhibit the same symptoms as those with CVS, including episodes of nausea, vomiting, and abdominal pain. However, while CVS can be caused by various factors, CHS is directly linked to cannabis use.

The potency of modern marijuana has increased significantly since legalization. Concentrations of THC, the primary psychoactive compound in marijuana, have risen from around 1-3% to levels exceeding 15%, with some strains reaching as high as 95%. This shift has led to a proliferation of products that are both more potent and appealing to consumers.

The consequences of this trend are far-reaching. In addition to the physical symptoms associated with CHS, research has shown a link between cannabis use and schizophrenia. Studies have found that daily use of high-potency marijuana is associated with a nearly five-fold increase in schizophrenia risk. While there may be a genetic predisposition to the condition, it’s clear that cannabis can exacerbate its development.

Dr. James Swartz notes that CHS often co-occurs with other mental health conditions, but whether this is due to self-medication or some other factor remains unclear. What is certain, however, is that quitting cannabis can be a daunting task for those affected by CHS.

The rise of CHS serves as a stark reminder that even with the best intentions, our actions can have unintended consequences. As we continue down this path of increasing cannabis potency and availability, we must be vigilant in monitoring its effects – not just on our physical health, but also on our collective well-being.

This disturbing trend raises questions about how far we will push the boundaries of marijuana’s potential before acknowledging its limits. The answer lies not in the weed itself, but in our willingness to confront the shadows that accompany it.